ReviewThe American journal of pathology2015
Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue.
Review in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Anchored random reverse primer sequencing for quantitative detection of novel gene fusions.Nature biomedical engineering · 2026Article
- IFDlong: a model-based isoform and fusion detector for accurate annotation and quantification of long-read RNA-seq data.Genome biology · 2026Article
- Deep spatial sequencing revealing differential immune responses in human hepatocellular carcinoma.Frontiers in cell and developmental biology · 2025Article
- Immuno-targeting the ectopic phosphorylation sites of PDGFRA generated by MAN2A1-FER fusion in HCC.Hepatology communications · 2024Article
- Roles of NOLC1 in cancers and viral infection.Journal of cancer research and clinical oncology · 2023Review
- Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer.Molecular oncology · 2023Article
- Fusion Gene Detection in Prostate Cancer Samples Enhances the Prediction of Prostate Cancer Clinical Outcomes from Radical Prostatectomy through Machine Learning in a Multi-Institutional Analysis.The American journal of pathology · 2023Article
- Virtual Gene Concept and a Corresponding Pragmatic Research Program in Genetical Data Science.Entropy (Basel, Switzerland) · 2021Review
- Detection of fusion gene transcripts in the blood samples of prostate cancer patients.Scientific reports · 2021Article
- Targetable gene fusions and aberrations in genitourinary oncology.Nature reviews. Urology · 2020Review
- Prediction of tumor location in prostate cancer tissue using a machine learning system on gene expression data.BMC bioinformatics · 2020Article
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma.Gastrointestinal tumors · 2019Article
- Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma.Oncotarget · 2019Article
- Identification of recurrent fusion genes across multiple cancer types.Scientific reports · 2019Article
- A New Era of Prostate Cancer Precision Medicine.Frontiers in oncology · 2019Review
- Interfering Expression of Chimeric TranscriptJournal of oncology · 2019Article
- Review
- Novel transcription-induced fusion RNAs in prostate cancer.Oncotarget · 2017Article
- Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene.Nature biotechnology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Fusion transcript formation is one of the fundamental mechanisms that drives the development of prostate cancer. Because of the advance of high-throughput parallel sequencing, many fusion transcripts have been discovered. However, the discovery rate of fusion transcripts specific for prostate cancer is lagging behind the discoveries made on chromosome abnormalities of prostate cancer. Recent analyses suggest that many fusion transcripts are present in both benign and cancerous tissues. Some of these fusion transcripts likely represent important components of normal gene expression in cells. It is necessary to identify the criteria and features of fusion transcripts that are specific for cancer. In this review, we discuss optimization of RNA sequencing depth for fusion transcript discovery and the characteristics of fusion transcripts in normal prostate tissues and prostate cancer. We also propose a new classification of cancer-specific fusion transcripts on the basis of their tail gene fusion protein product and the roles that these fusions may play in cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.